--- title: "Enovis Corporation (ENOV.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/ENOV.US.md" symbol: "ENOV.US" name: "Enovis Corporation" industry: "Health Care Equipment" --- # Enovis Corporation (ENOV.US) | Item | Detail | |------|--------| | Industry | Health Care Equipment | | Location | US Market | | Website | [www.enovis.com](https://www.enovis.com) | ## Company Profile Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers o... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-16T04:30:12.000Z **Overall: C (0.59)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 59 / 184 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 11.57% | | | Net Profit YoY | -1047.04% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 0.62 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 1.25B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 2.23B | | **Multi Score**: C #### Profit Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -51.11% | E | | Profit Margin | -61.22% | E | | Gross Margin | 60.19% | A | #### Growth Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 11.57% | B | | Net Profit YoY | -1047.04% | E | | Total Assets YoY | -20.12% | E | | Net Assets YoY | -39.29% | E | #### Cash Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | -163.35% | D | | OCF YoY | 11.57% | B | #### Operating Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.45 | C | #### Debt Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 54.35% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Enovis Corporation", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "D", "indicators": [ { "name": "ROE", "value": "-51.11%", "rating": "E" }, { "name": "Profit Margin", "value": "-61.22%", "rating": "E" }, { "name": "Gross Margin", "value": "60.19%", "rating": "A" } ] }, { "name": "Growth", "grade": "C", "indicators": [ { "name": "Revenue YoY", "value": "11.57%", "rating": "B" }, { "name": "Net Profit YoY", "value": "-1047.04%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-20.12%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-39.29%", "rating": "E" } ] }, { "name": "Cash", "grade": "C", "indicators": [ { "name": "Cash Flow Margin", "value": "-163.35%", "rating": "D" }, { "name": "OCF YoY", "value": "11.57%", "rating": "B" } ] }, { "name": "Operating", "grade": "C", "indicators": [ { "name": "Turnover", "value": "0.45", "rating": "C" } ] }, { "name": "Security", "grade": "C", "indicators": [ { "name": "Gearing Ratio", "value": "54.35%", "rating": "C" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A | | 02 | Delcath (US.DCTH) | C | A | A | A | A | A | | 03 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B | | 04 | Stryker (US.SYK) | A | B | C | C | B | B | | 05 | Boston Scientific (US.BSX) | B | B | E | A | B | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.91 | 80/181 | - | - | - | | PB | 0.62 | 16/181 | 0.79 | 0.72 | 0.67 | | PS (TTM) | 0.56 | 19/181 | 0.92 | 0.82 | 0.71 | | Dividend Yield | 0.00% | - | - | - | - | ## Institutional View ### Analyst Rating Distribution > As of 2026-01-30T05:00:00.000Z Total Analysts: **12** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 9 | 75% | | Overweight | 2 | 17% | | Hold | 1 | 8% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 21.77 | | Highest Target | 55.00 | | Lowest Target | 33.00 | ## References - [Company Overview](https://longbridge.com/en/quote/ENOV.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/ENOV.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/ENOV.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.